NCT01473043View on ClinicalTrials.gov

Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

NO_LONGER_AVAILABLEEXPANDED_ACCESS

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Axitinib

5mg twice daily \[BD\] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol

Trial Locations (4)

3355

Pfizer Investigational Site, Wendouree

4814

Pfizer Investigational Site, Douglas

7000

Pfizer Investigational Site, Hobart

H2X 1N8

Pfizer Investigational Site, Montreal